Two hundred CHD equivalent ( CHD-RP20 ) , ILHDL-C cases were randomly assigned for treatment either with atorvastatin 10 mg/day ( n = 70 ) , micronized fenofibrate 160 mg/day ( n = 65 ) or niacin-extended release ( ER ) 750 mg/day ( n = 65 ) .